Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study

The R2 (lenalidomide-rituximab) and R2 with bendamustine (R2B) regimens are both feasible in relapsed/refractory follicular lymphoma (R/R FL), but prospective phase II data on R2B are lacking. In this multinational, prospective, randomised, non-comparative trial, patients with R/R FL were randomise...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Marie José Kersten, Martin Dreyling, Kim M. Linton, Dana Chitu, Gerben J.C. Zwezerijnen, Sanne H. Tonino, Marcel Kap, Roberto Liu, Christel van Hooije, Martine E.D. Chamuleau, Hein P.J. Visser, Eva de Jongh, Erik A.F. Marijt, Maria B.L. Leys, Yavuz M. Bilgin, Jan Dürig, Pamela McKay, Tjeerd Snijders, Andrew Pettitt, Monique C. Minnema, Gabriele Prange-Krex, Marloes L.H. Cuijpers, Lara H. Bohmer, Lidwine W. Tick, Axel Florschutz, Matthijs Silbermann, Rob Fijnheer, Aart Beeker, Nelleke Tolboom, Cristina Mitea, Anne I.J. Arens, Sanne E. Wiegers, Martijn W. Heymans, Wolfram Klapper, Sarah E. Coupland, Daphne de Jong, Jeanette K. Doorduijn, Josée M. Zijlstra
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Ferrata Storti Foundation 2026-04-01
سلاسل:	Haematologica
الوصول للمادة أونلاين:	https://haematologica.org/article/view/14120
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!